<DOC>
	<DOC>NCT01531647</DOC>
	<brief_summary>This open-label, multiple dose, single sequence crossover study will evaluate the drug-drug interaction between danoprevir/low-dose ritonavir and raltegravir in healthy volunteers. Subjects will receive raltegravir on Days 1-4 and, after a washout period of 3 days, danoprevir and low-dose ritonavir on Days 8-21, in combination with raltegravir on Days 18-21.</brief_summary>
	<brief_title>A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Healthy nonsmoking male and female adults, 18 55 years of age, inclusive Healthy status defined by absence of evidence of any active or chronic disease Medical history without major, recent, or ongoing pathology Weight &gt;/= 50.0 kg Body mass index (BMI) 18.0 320 kg/m2 Willingness to abstain from alcohol, xanthinecontaining beverages or food (e.g. coffee, tea, cola, chocolate, "energy drinks") from 48 hours prior to entry in the clinical site until discharge Females of childbearing potential and males and their female partners of childbearing potential must agree to use 2 forms of contraception, one of which must be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception are condom and diaphragm; acceptable nonbarrier forms of contraception for this study are nonhormonal intrauterine device (IUD) and/or spermicide Pregnant or lactating females or males with female partners who are pregnant or lactating Any history of clinically significant cardiovascular or cerebrovascular disease, hypertension, and/or infections Positive test for drugs of abuse at screening or prior to admission to the clinical site during any study period Positive for hepatitis B, hepatitis C or HIV infection Current smokers or subjects who have discontinued smoking less than 6 months prior to first dose of study medication Use of hormonal contraceptives within 30 days before the first dose of study medication History of clinically significant drugrelated allergy (such as anaphylaxis) or hepatotoxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>